MetLife Investment Management’s Olema Pharmaceuticals OLMA Stock Holding History

MetLife Investment Management’s Portfolio OLMA Stock Details OLMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$582K	Buy	46,500 +7,980	+21%	+$107K	﹤0.01%	1831
2026 Q1	$574K	Buy	38,520 +5,020	+15%	+$112K	﹤0.01%	1686
2025 Q4	$838K	Sell	33,500 -4,120	-11%	-$73.3K	﹤0.01%	1529
2025 Q3	$368K	Hold	37,620	–	–	﹤0.01%	1958
2025 Q2	$160K	Buy	37,620 +19,945	+113%	+$88.9K	﹤0.01%	2299
2025 Q1	$66.5K	Sell	17,675 -6,020	-25%	-$30.3K	﹤0.01%	2659
2024 Q4	$138K	Hold	23,695	–	–	﹤0.01%	2479
2024 Q3	$283K	Hold	23,695	–	–	﹤0.01%	2100
2024 Q2	$256K	Buy	23,695 +8,790	+59%	+$95.3K	﹤0.01%	2093
2024 Q1	$169K	Hold	14,905	–	–	﹤0.01%	2289
2023 Q4	$209K	Hold	14,905	–	–	﹤0.01%	2222
2023 Q3	$184K	Hold	14,905	–	–	﹤0.01%	2265
2023 Q2	$135K	Buy	+14,905	New	+$90K	﹤0.01%	2509
2022 Q1	–	Sell	-9,573	Closed	-$89.6K	–	2756
2021 Q4	$89.6K	Hold	9,573	–	–	﹤0.01%	2438
2021 Q3	$264K	Buy	9,573 +3,962	+71%	+$107K	﹤0.01%	1908
2021 Q2	$157K	Hold	5,611	–	–	﹤0.01%	2304
2021 Q1	$186K	Buy	+5,611	New	+$240K	﹤0.01%	2097

Other funds holding OLMA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

MetLife Investment Management's OLMA Position: Q2 2026 in Review

MetLife Investment Management increased its Olema Pharmaceuticals (OLMA) stake by 21% in Q2 2026, buying an estimated $107K and bringing the position to 46,500 shares worth $582K. The position accounts for ﹤0.01% of the portfolio, ranked #1831.

MetLife Investment Management first reported a position in OLMA in Q1 2021 and has held it in 17 quarters since. The position peaked at $838K in Q4 2025. 185 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

MetLife Investment Management held 46,500 shares of Olema Pharmaceuticals worth $582K as of Q2 2026.
MetLife Investment Management bought 7,980 Olema Pharmaceuticals shares in Q2 2026, an estimated $107K.
Olema Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1831 holding.
MetLife Investment Management first reported a position in Olema Pharmaceuticals in Q1 2021 and has held it in 17 quarters since.
MetLife Investment Management's Olema Pharmaceuticals position peaked at $838K in Q4 2025.
185 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.